Cihan Yurdaydin Selected Research

Hepatitis D

1/2022	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.
1/2021	Developing New Therapies for Delta Hepatitis: The Race Is On.
1/2021	A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
1/2021	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
1/2019	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
1/2018	Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
1/2017	Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.
12/2015	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
8/2015	Therapy of Delta Hepatitis.
1/2014	Anti-HDV IgM as a marker of disease activity in hepatitis delta.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cihan Yurdaydin Research Topics

Disease

22	Chronic Hepatitis B 11/2020 - 09/2004
19	Infections 01/2022 - 10/2002
18	Fibrosis (Cirrhosis) 06/2021 - 10/2002
14	Hepatitis D 01/2022 - 08/2002
13	Liver Diseases (Liver Disease) 06/2021 - 08/2002
12	Chronic Hepatitis D 01/2022 - 08/2002
11	Hepatocellular Carcinoma (Hepatoma) 11/2020 - 07/2005
10	Hepatitis B 01/2022 - 08/2002
7	Chronic Hepatitis (Chronic Active Hepatitis) 01/2021 - 10/2002
3	Liver Neoplasms (Liver Cancer) 01/2021 - 10/2012
3	Virus Diseases (Viral Diseases) 01/2019 - 07/2003
3	Hepatitis 09/2012 - 03/2005
2	Acute Liver Failure (Fulminant Hepatic Failure) 01/2021 - 07/2010
2	Coinfection 09/2020 - 08/2015
2	Liver Failure 02/2012 - 07/2003
2	Liver Cirrhosis (Hepatic Cirrhosis) 02/2012 - 06/2007
2	Cholestasis 02/2006 - 04/2005
2	Fatigue 04/2005 - 09/2004
1	COVID-19 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	End Stage Liver Disease 12/2020
1	Hepatolenticular Degeneration (Wilson's Disease) 01/2019
1	Superinfection 08/2015
1	Massive Hepatic Necrosis 08/2015
1	Disease Progression 01/2014
1	Chronic Hepatitis C 06/2011
1	Hepatitis C 04/2011
1	Jaundice (Icterus) 07/2010
1	Persistent Infection 09/2009
1	Alcoholism (Alcohol Abuse) 09/2009
1	Viremia 06/2006
1	Non-alcoholic Fatty Liver Disease 11/2005
1	Obesity 11/2005
1	Type 2 Diabetes Mellitus (MODY) 11/2005
1	Fatty Liver 11/2005

Drug/Important Bio-Agent (IBA)

16	InterferonsIBA 01/2022 - 08/2002
16	Lamivudine (Epivir)FDA Link 01/2017 - 08/2002
12	Hepatitis B e AntigensIBA 01/2017 - 07/2003
11	RNA (Ribonucleic Acid)IBA 10/2021 - 08/2002
11	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2021 - 07/2003
10	Antiviral Agents (Antivirals)IBA 01/2021 - 06/2006
10	entecavir FDA Link 11/2020 - 06/2006
8	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2003
8	Tenofovir (Viread)FDA Link 11/2020 - 01/2014
5	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 07/2003
5	Pharmaceutical PreparationsIBA 02/2013 - 07/2010
4	lonafarnib (SCH 66336)IBA 01/2022 - 10/2015
4	AlbuminsIBA 06/2021 - 06/2011
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2011
3	AntigensIBA 01/2022 - 07/2003
3	peginterferon alfa-2a (Pegasys)FDA Link 01/2019 - 09/2004
3	adefovirIBA 12/2015 - 01/2012
3	Alanine Transaminase (SGPT)IBA 09/2012 - 07/2003
2	Ritonavir (Norvir)FDA Link 01/2022 - 01/2017
2	TransferasesIBA 01/2017 - 06/2011
2	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 04/2011
2	NucleosidesIBA 01/2017 - 08/2002
2	EnzymesIBA 12/2015 - 08/2002
2	Immunoglobulin M (IgM)IBA 01/2014 - 01/2012
2	Proteins (Proteins, Gene)FDA Link 02/2012 - 03/2005
2	PPAR alphaIBA 12/2008 - 11/2005
2	Hepatitis B Core AntigensIBA 06/2006 - 03/2003
2	Serotonin (5 Hydroxytryptamine)IBA 02/2006 - 04/2005
1	Circular DNAIBA 01/2022
1	Virulence Factors (Pathogenicity Factors)IBA 10/2021
1	Transaminases (Aminotransferases)IBA 01/2021
1	CopperIBA 01/2019
1	Emtricitabine (Emtriva)FDA Link 01/2017
1	sofosbuvir drug combination ledipasvirIBA 01/2017
1	nasIBA 01/2017
1	Cholinesterases (Cholinesterase)IBA 01/2017
1	lipoarabinomannan (LAM)IBA 01/2017
1	RacivirIBA 01/2017
1	daclatasvirIBA 01/2017
1	paritaprevirIBA 01/2017
1	ombitasvirIBA 01/2017
1	NucleotidesIBA 01/2017
1	dasabuvirIBA 01/2017
1	SofosbuvirIBA 01/2017
1	clemizoleIBA 02/2013
1	Interferon Type IIBA 01/2012
1	Laminin (Merosin)IBA 06/2011
1	CollagenIBA 06/2011
1	Hyaluronic Acid (Hyaluronan)IBA 06/2011
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 06/2011
1	Collagen Type III (Type III Collagen)IBA 06/2011
1	Telbivudine FDA Link 05/2011
1	AflatoxinsIBA 09/2009
1	Surface Antigens (Surface Antigen)IBA 04/2009
1	Taurine FDA Link 06/2007
1	Hydroxyproline (4 Hydroxyproline)IBA 06/2007
1	adefovir dipivoxil (Hepsera)FDA Link 01/2007
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 06/2006
1	LipidsIBA 11/2005
1	Neurotransmitter Agents (Neurotransmitter)IBA 04/2005

Therapy/Procedure

25	Therapeutics 01/2021 - 08/2002
8	Liver Transplantation 01/2021 - 01/2012
1	Duration of Therapy 01/2018
1	Aftercare (After-Treatment) 12/2015
1	Lasers (Laser) 02/2012